The newly approved methastatic Renal Cell Cancer (mRCC) Phase 1/2a trial began in Q4 2024, and Genenta expects to treat six patients by the end of the first half of 2025, while continuing progress ...
During the occurrence and development of tumors, a microenvironment with high rate of tumor survival, proliferation and distant metastasis is formed, which can reduce the killing effect of tumor cells ...